Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 52, n° 3S
page P1 (mars 2005)
Doi : 10.1016/j.jaad.2004.10.020
Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Final phase IIIb study results

Alice Gottlieb, MD, UMDNJ—Robert Wood Johnson Medical School, New Brunswick, NJ, United States; Kenneth Gordon, MD, Loyola University Medical Center, Maywood, IL, United States; Tiffani Hamilton, MD, Atlanta Dermatology, Vein & Research Center, LLC, Alpharetta, GA, United States; Craig Leonardi, MD, Saint Louis University School of Medicine, St. Louis, MO, United States

100 percent sponsored by Genentech, Inc.

Top of the page

© 2005  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline